IGF-II transgenic mice display increased aberrant colon crypt multiplicity and tumor volume after 1,2-dimethylhydrazine treatment

Journal of Carcinogenesis

Volumn 5, Issue , 2006, Pages

  Diehl, Daniela ^a   Oesterle, Doris ^b   Elmlinger, Martin W ^c   Hoeflich, Andreas ^a   Wolf, Eckhard ^a   Lahm, Harald ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIMETHYLHYDRAZINE; BETA CATENIN; SOMATOMEDIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SIZE; CARCINOGENESIS; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; COLON ADENOMA; COLON CARCINOMA; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSOL; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; INTESTINE CRYPT; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WILD TYPE;

EID: 33845193942     PISSN: 14773163     EISSN: 14773163     Source Type: Journal    
DOI: 10.1186/1477-3163-5-24     Document Type: Article

References (54)

1. Bird RP: Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995, 93:55-71.
2. Cheng L, Lai MD: Aberrant crypt foci as microscopic precursors of colorectal cancer. World J Gastroenterol 2003, 9:2642-2649.
3. Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA, Stellato TA: Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991, 51:1564-1567.
4. McLellan EA, Bird RP: Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res 1988, 48:6187-6192.
5. McLellan EA, Medline A, Bird RP: Dose response and proliferative characteristics of aberrant crypt foci: putative preneoplastic lesions in rat colon. Carcinogenesis 1991, 12:2093-2098.
6. Roncucci L, Pedroni M, Vaccina F, Benatti P, Marzona L, De Pol A: Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. Cell Prolif 2000, 33:1-18.
7. Jackson PE, Cooper DP, O'Connor PJ, Povey AC: The relationship between 1,2-dimethylhydrazine dose and the induction of colon tumours: tumour development in female SWR mice does not require a K-ras mutational event. Carcinogenesis 1999, 20:509-513.
8. Tudek B, Bird RP, Bruce WR: Foci of aberrant crypts in the colons of mice and rats exposed to carcinogens associated with foods. Cancer Res 1989, 49:1236-1240.
9. Jackson PE, Cooper DP, Meyer TA, Wood M, Povey AC, Margison GP: Formation and persistence of O(6)-methylguanine in the mouse colon following treatment with 1,2-dimethylhydrazine as measured by an O(6)-alkylguanine-DNA alkyltransferase inactivation assay. Toxicol Lett 2000, 115:205-212.
10. Xiao W, Nowak M, Laferte S, Fontanie T: Mutagenicity and toxicity of the DNA alkylation carcinogens 1,2-dimethylhydrazine and azoxymethane in Escherichia coli and Salmonella typhimurium. Mutagenesis 1996, 11:241-245.
11. Blum CA, Xu M, Orner GA, Fong AT, Bailey GS, Stoner GD, Horio DT, Dashwood RH: beta-Catenin mutation in rat colon tumors initiated by 1,2-dimethylhydrazine and 2-amino-3-methylimidazo[4,5-f]quioline, and the effect of post-initiation treatment with chlorophyllin and indole-3-carbinol. Carcinogenesis 2001, 22:315-320.
12. Jacoby RF, Llor X, Teng BB, Davidson NO, Brasitus TA: Mutations in the K-ras oncogene induced by 1,2-dimethylhydrazine in preneoplastic and neoplastic rat colonic mucosa. J Clin Invest 1991, 87:624-630.
13. Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP: Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med 1998, 4:1276-1280.
14. Lahm H, Amstad P, Wyniger J, Yilmaz A, Fischer JR, Schreyer M, Givel JC: Blockade of the insulin-like growth-factor-1 receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop. Int J Cancer 1994, 58:452-459.
15. Diehl D, Hoeflich A, Wolf E, Lahm H: Insulin-like growth factor (IGF)-binding protein-4 inhibits colony formation of colorectal cancer cells by IGF-independent mechanisms. Cancer Res 2004, 64:1600-1603.
16. Morali OG, Delmas V, Moore P. Jeanney C, Thiery JP, Larue L: IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001, 20:4942-4950.
17. Iwamoto M, Ahnen DJ, Franklin WA, Maltzman TH: Expression of beta-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis 2000, 21:1935-1940.
18. Oving IM, Clevers HC: Molecular causes of colon cancer. Eur J Clin Invest 2002, 32:448-457.
19. Sinha D, Wang Z, Ruchalski KL, Levine JS, Krishnan S, Lieberthal W, Schwartz JH, Borkan SC: Lithium activates the Wnt and phosphatidylinositol 3-kinase Akt signaling pathways to promote cell survival in the absence of soluble survival factors. Am J Physiol Renal Physiol 2005, 288:F703-F713.
20. Chen T, Yang I, Irby R, Shain KH, Wang HG, Quackenbush J, Coppola D, Cheng JQ, Yeatman TJ: Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Res 2003, 63:4368-4374.
21. McColl BK, Loughran SJ, Davydova N, Stacker SA, Achen MG: Mechanisms of lymphangiogenesis: targets for blocking the metastatic spread of cancer. Curr Cancer Drug Targets 2005, 5:561-571.
22. Bjorndahl M, Cao R, Nissen LJ, Clasper S, Johnson LA, Xue Y, Zhou Z, Jackson D, Hansen AJ, Cao Y: Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci U S A 2005, 102:15593-15598.
23. Hunt KJ, Toniolo P, Akhmedkhanov A, Lukanova A, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E, Kaaks R: Insulin-like growth factor II and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prev 2002, 11:901-905.
24. Wolf E, Kramer R, Blum WF, Foll J, Brem G: Consequences of postnatally elevated insulin-like growth factor-II in transgenic mice: endocrine changes and effects on body and organ growth. Endocrinology 1994, 135:1877-1886.
25. Lahm H, Gittner K, Krebs O, Sprague L, Deml E, Oesterle D, Hoeflich A, Wanke R, Wolf E: Diethylnitrosamine induces long-lasting re-expression of insulin-like growth factor II during early stages of liver carcinogenesis in mice. Growth Horm IGF Res 2002, 12:69-79.
26. Schipper DL, Wagenmans MJ, Peters WH, Wagener DJ: Significance of cell proliferation measurement in gastric cancer. Eur J Cancer 1998, 34:781-790.
27. Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, Safra T, Shiloni E, Raz I: Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999, 44:704-708.
28. Wolf E, Hoeflich A, Lahm H: What is the function of IGF-II in postnatal life? Answers from transgenic mouse models. Growth Horm IGF Res 1998, 8:185-193.
29. Hassan AB, Howell JA: Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. Cancer Res 2000, 60:1070-1076.
30. Lamonerie T, Lavialle C, de Galle B, Binoux M, Brison O: Constitutive or inducible overexpression of the IGF-2 gene in cells of a human colon carcinoma cell line. Exp Cell Res 1995, 216:342-351.
31. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
32. Cottrell S, Bicknell D, Kaklamanis L, Bodmer WF: Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet 1992, 340:626-630.
33. Roncucci L, Stamp D, Medline A, Cullen JB, Bruce WR: Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 1991, 22:287-294.
34. Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, Adami HO, Mantzoros C: IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 1999, 83:15-17.
35. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R: Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999, 19:3278-3288.
36. Zhao R, Berho M, Nogueras J, Sands D, Weiss E, Wexner S, Giardiello FM, Cruz-Correa M: Positive correlation of insulin-like growth factor-II with proliferating cell index in patients with colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2005, 14:1819-1822.
37. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M: Insulin-like growth factor-I induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res 2001, 61:7318-7324.
38. Kundu AK, Nagaoka M, Chowdhury EH, Hirose S, Sasagawa T, Akaike T: IGF-I induces growth, survival and morphological change of primary hepatocytes on a galactose-bared polymer through both MAPK and beta-catenin pathways. Cell Struct Funct 2003, 28:255-263.
39. Takahashi M, Nakatsugi S, Sugimura T, Wakabayashi K: Frequent mutations of the beta-catenin gene in mouse colon tumors induced by azoxymethane. Carcinogenesis 2000, 21:1117-1120.
40. Fasolini M, Wu X, Flocco M, Trosset JY, Oppermann U, Knapp S: Hot spots in Tcf4 for the interaction with beta-catenin. J Biol Chem 2003, 278:21092-21098.
41. Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, Soderkvist P: Mutation analysis of the BRAF, ARAF and RAF-I genes in human colorectal adenocarcinomas. Carcinogenesis 2004, 25:527-533.
42. LeRoith D, Roberts CT Jr.: The insulin-like growth factor system and cancer. Cancer Lett 2003, 195:127-137.
43. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H: Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784-1787.
44. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
45. Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003, 15:740-746.
46. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454.
47. Butt AJ, Firth SM, Baxter RC: The IGF axis and programmed cell death. Immunol Cell Biol 1999, 77:256-262.
48. Longo KA, Kennell JA, Ochocinska MJ, Ross SE, Wright WS, MacDougald OA: Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J Biol Chem 2002, 277:38239-38244.
49. Arai T, Kino I: Role of apoptosis in modulation of the growth of human colorectal tubular and villous adenomas. J Pathol 1995, 176:37-44.
50. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E: Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000, 92:1592-1600.
51. Renehan AG, Jones J, Potten CS, Shalet SM, O'Dwyer ST: Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 2000, 83:1344-1350.
52. Naishiro Y, Yamada T, Idogawa M, Honda K, Takada M, Kondo T, Imai K, Hirohashi S: Morphological and transcriptional responses of untransformed intestinal epithelial cells to an oncogenic beta-catenin protein. Oncogene 2005, 24:3141-3153.
53. Bukholm IR, Bondi J, Wiik P, Nesland JM, Andersen SN, Bakka A, Bukholm G: Presence of isolated tumour cells in mesenteric lymph nodes predicts poor prognosis in patients with stage II colon cancer. Eur J Surg Oncol 2003, 29:862-866.
54. Jackson DG, Prevo R, Clasper S, Banerji S: LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 2001, 22:317-321.